AAD 2020 Highlights Podcast

 

In this episode, Dr Rachel Giles guides you through the following sessions:

1. 
   
   1. Simpson EL, et al. Baricitinib, an Oral, Reversible Janus Kinase-1 and -2 Inhibitor, for Atopic Dermatitis: Head and Neck Response Across Two Phase 3 Studies. P15059; AAD Virtual Meeting Experience, 12-14 June 2020.
   2. Khanna R, et al. Intranasal butorphanol as a rescue therapy for the treatment of intractable pruritus. P17132, AAD Virtual Meeting Experience, 12-14 June 2020.
   3. Lewinson RT, et al. Depression as a risk factor for the development of psoriasis. P16742, AAD Virtual Meeting Experience, 12-14 June 2020.
   4. Warren RB. Risankizumab versus secukinumab in patients with moderate-to-severe plaque psoriasis: a phase 3 trial. Late-breaking abstract, AAD Virtual Meeting Experience, 12-14 June 2020.
   5. Hu J, et al. Impact of Obesity and Body Parameters on Pembrolizumab Toxicity and Efficacy in Patients with Advanced Melanoma. Late-breaking abstract, AAD Virtual Meeting Experience, 12-14 June 2020.
   6. Paller A. Dupilumab significantly improves atopic dermatitis in children aged =6 to <12 years: results from phase 3 Trial (LIBERTY AD PEDS). Late-breaking abstract, AAD Virtual Meeting Experience, 12-14 June 2020.

Posted on 7 August, 202023 February, 2021